RSV Vaccines: What the Evidence Shows

Respiratory syncytial virus (RSV) often causes a mild cold, but it can also lead to bronchiolitis, pneumonia, breathing failure, hospitalization, and death. Infants, older adults, people with chronic heart or lung disease, and those with weakened immune systems face the greatest risk.

RSV prevention now includes vaccines for eligible older adults and pregnant people, along with long-acting preventive antibodies for infants. The strongest evidence shows reductions in severe lower-respiratory disease, emergency visits, and hospitalization—not the elimination of every infection.

That distinction matters. A claim that RSV vaccines “slash infections” can overstate the evidence unless it identifies the outcome measured. A vaccine may substantially reduce hospitalization while providing less complete protection against mild or asymptomatic infection. Results also vary by product, age group, season, circulating strains, and time since vaccination.

What Is RSV?

RSV usually begins with symptoms such as:

• Runny nose
• Cough
• Fever
• Wheezing
• Reduced appetite
• Fatigue

Symptoms can resemble influenza, COVID-19, and other respiratory infections. Most people recover without specific treatment, but the infection can progress from the upper airways to the lower respiratory tract.

Severe RSV disease can cause bronchiolitis, pneumonia, dehydration, and difficulty breathing. Some patients require oxygen, intensive care, or mechanical ventilation.

Higher-risk groups include:

• Very young infants
• Adults aged 60 and older
• People with chronic obstructive pulmonary disease or asthma
• People with heart failure or other cardiovascular disease
• People with diabetes or chronic kidney disease
• Frail adults and nursing-home residents
• People with weakened immune systems

RSV can worsen existing heart or lung disease. Infants may deteriorate quickly because their airways are small and their immune systems are still developing.

RSV spreads through respiratory droplets, close contact, and contaminated surfaces. Vaccination does not replace handwashing, good ventilation, staying home while sick, or protecting vulnerable people from close exposure. CDC

How RSV Prevention Works

RSV vaccines present the immune system with a harmless target associated with the virus. The body produces antibodies and immune memory, allowing a faster response after later exposure.

This protection is not guaranteed sterilizing immunity. A vaccinated person can still become infected, especially after substantial exposure or as immunity declines. The primary public-health goal is to reduce symptomatic illness and, most importantly, severe lower-respiratory disease.

Current prevention uses three main approaches:

1. RSV vaccines for eligible older adults
2. RSV vaccination during pregnancy
3. Long-acting preventive antibodies for infants

Preventive antibodies are not traditional vaccines. They provide ready-made antibodies rather than training the recipient’s immune system. Nirsevimab is designed to protect eligible infants during their first RSV season and certain high-risk children entering a second season. Protection is temporary and timed to the period of greatest vulnerability. CDC

Recommendations depend on national guidance, product authorization, age, pregnancy status, medical history, and local RSV circulation.

What the Effectiveness Data Show

Clinical trials commonly measure:

• RSV-related lower-respiratory-tract disease
• Severe lower-respiratory illness
• Emergency medical visits
• Hospitalization
• Oxygen use or other respiratory support

These outcomes matter more than a simple count of positive tests. Preventing mild infection has value, but preventing pneumonia, hospitalization, or respiratory failure provides the greatest benefit to patients and health systems.

A vaccinated person may still contract RSV but experience a shorter or less severe illness. Therefore, effectiveness against hospitalization should not be treated as effectiveness against every infection.

In a phase 3 trial of Arexvy in older adults, vaccine efficacy against RSV-related lower-respiratory-tract disease was approximately 82% during the first RSV season. In a separate phase 3 trial of Abrysvo in adults aged 60 and older, efficacy was approximately 67% against RSV-related lower-respiratory disease and about 86% against severe disease during the first season. These studies used different designs and outcome definitions, so the figures should not be ranked as though they came from a head-to-head trial. FDA

Effectiveness estimates vary according to:

• Participant age and health status
• Vaccine product and formulation
• RSV season and circulating strains
• Trial or real-world study design
• Definition of infection or severe disease
• Time since vaccination
• Sample size and follow-up duration
• Healthcare access and testing patterns

A credible estimate should identify the study population, outcome, follow-up period, and confidence interval when available.

Clinical Efficacy Versus Real-World Effectiveness

Randomized trials estimate efficacy under controlled conditions. Real-world studies estimate effectiveness in broader populations, including people with frailty, multiple medical conditions, and different vaccination histories.

Observational studies can be affected by healthcare-seeking behavior, vaccination access, prior infection, testing patterns, and differences between vaccinated and unvaccinated groups. Even so, they show how protection performs outside controlled research and whether vaccination reduces hospital burden.

RSV Vaccines for Older Adults

Immune function changes with age, which can weaken the response to infection and slow recovery. RSV may also destabilize chronic conditions such as chronic obstructive pulmonary disease, asthma, heart failure, diabetes, chronic kidney disease, frailty, and immune suppression. Long-term-care facilities may face additional exposure because respiratory viruses spread efficiently in group settings.

In the United States, CDC guidance recommends one RSV vaccine dose for all adults aged 75 and older and for adults aged 60 through 74 who face increased risk of severe RSV disease. Risk factors include chronic medical conditions, frailty, residence in a nursing home or other long-term-care facility, and certain social or environmental circumstances. Guidance may differ in other countries and can change as evidence develops. CDC

Vaccination is generally most useful before seasonal RSV transmission rises. In many regions, late summer or early fall is the usual vaccination period, but timing varies by location. People who miss the preferred window may still benefit later, depending on local circulation and individual risk.

RSV Vaccination During Pregnancy

During pregnancy, antibodies produced by the pregnant person can cross the placenta and provide passive protection to the fetus. This strategy protects newborns during the first months of life, when severe RSV disease is most concerning.

In the MATISSE phase 3 trial, maternal vaccination reduced medically attended severe RSV lower-respiratory disease in infants by approximately 82% during the first three months after birth and approximately 69% during the first six months. New England Journal of Medicine

Timing depends on gestational age, product authorization, the expected RSV season, and national guidance. In the United States, maternal RSV vaccination is recommended during a specific pregnancy window, generally between 32 and 36 weeks’ gestation, when seasonal protection is appropriate. CDC

Healthcare professionals may recommend maternal vaccination or an infant preventive antibody. Factors include the timing of vaccination and delivery, the RSV season, the infant’s medical risk, product availability, and the expected level of maternal antibody protection. Most infants do not need both approaches.

Protecting Infants

Infants have small airways and developing immune systems. Swelling and mucus can interfere with breathing, and congestion can make feeding difficult and cause dehydration.

Warning signs include:

• Fast or difficult breathing
• Ribs pulling inward with each breath
• Pauses in breathing
• Blue or gray lips or skin
• Poor feeding
• Fewer wet diapers
• Unusual sleepiness, weakness, or difficulty waking

Seek urgent medical care when an infant has breathing difficulty, pauses in breathing, signs of dehydration, or rapidly worsening symptoms.

Nirsevimab provides ready-made antibodies and does not require the infant to develop an immune response first. Eligibility can depend on age, birth timing, prematurity, chronic lung disease, serious heart disease, immune compromise, maternal RSV vaccination, local recommendations, and supply. Protection is temporary, unlike the immune memory that vaccines aim to create. CDC

Safety and Side Effects

Common RSV vaccine reactions include:

• Pain, redness, or swelling at the injection site
• Fatigue
• Headache
• Muscle aches
• Joint pain
• Fever

These reactions are generally temporary. Severe or persistent symptoms require medical advice. Emergency care is appropriate for facial swelling, difficulty breathing, widespread hives, or sudden weakness.

Regulators and public-health agencies continue to monitor safety after authorization. A medical event reported after vaccination does not automatically prove that the vaccine caused it. Researchers compare reported events with expected background rates and investigate possible safety signals.

The benefit-risk decision depends on age, pregnancy status, chronic conditions, exposure risk, vaccine product, current RSV activity, and the latest safety evidence. A clinician can review individual risks, contraindications, and precautions.

How to Interpret Claims That RSV Vaccines “Slash Infections”

Check the exact endpoint. Studies may measure laboratory-confirmed infection, symptomatic illness, lower-respiratory disease, emergency visits, hospitalization, respiratory support, or death.

An 80% reduction in severe disease does not necessarily mean an 80% reduction in all RSV infections. The headline must match the measured outcome.

Also check whether the evidence comes from a randomized trial or an observational study. Review the publication date, study design, sample size, follow-up period, and confidence intervals. Guidance can change as new products, safety data, effectiveness findings, and seasonal patterns emerge.

What Research Still Needs to Answer

Researchers continue to study how long protection lasts across multiple seasons, how products compare for different groups, and whether prevention reduces recurrent wheezing, chronic lung disease exacerbations, cardiovascular complications, or long-term healthcare use. These questions require careful study before associations become established causal claims.

Practical Takeaways

• RSV vaccines and infant preventive antibodies reduce the risk of severe disease.
• The clearest evidence concerns lower-respiratory illness, emergency care, and hospitalization.
• Vaccination does not guarantee that infection will not occur.
• Eligibility depends on age, pregnancy status, medical risk, product authorization, and local guidance.
• Maternal vaccination and infant preventive antibodies are usually alternative strategies.
• Seek urgent help for infant breathing difficulty, pauses in breathing, blue or gray skin, poor feeding, or dehydration.
• Evaluate effectiveness claims by their outcome, study design, population, and follow-up period.

Conclusion

RSV prevention has improved substantially. Vaccines for older adults and pregnant people, together with long-acting antibodies for infants, reduce the risk of serious disease in groups facing the greatest danger.

The strongest success is not the elimination of every RSV infection. It is the reduction of severe lower-respiratory disease, emergency care, and hospitalization. A vaccinated person can still become infected, but protection may prevent the illness from becoming dangerous.

Eligible adults, pregnant people, and infant caregivers should review current protection options before local RSV activity increases. Anyone with difficult breathing, dehydration, blue or gray skin, severe weakness, or rapidly worsening symptoms should seek urgent medical care.

Frequently Asked Questions

Do RSV vaccines prevent all RSV infections?

No. They reduce the risk of illness and severe disease, but vaccinated people can still become infected.

Who should receive an RSV vaccine?

Recommendations vary by country. In the United States, vaccination is routinely recommended for adults aged 75 and older and certain adults aged 60 through 74 at increased risk. Pregnant people may also be eligible during a specific pregnancy window.

How do RSV vaccines differ from infant preventive antibodies?

Vaccines stimulate the immune system to create protection. Preventive antibodies provide ready-made protection, often for an infant’s first RSV season.

Can an RSV vaccine be given with other vaccines?

It may be possible to receive an RSV vaccine during the same visit as other recommended vaccines. Product-specific guidance and individual health factors affect the decision.

What are common RSV vaccine side effects?

Common effects include injection-site pain, fatigue, headache, muscle aches, joint pain, and fever. Severe or persistent symptoms require medical advice.

When should someone seek urgent care?

Seek urgent care for difficult or fast breathing, pauses in breathing, blue or gray skin, severe weakness, dehydration, inability to feed, or rapidly worsening symptoms.